Đang chuẩn bị liên kết để tải về tài liệu:
Efficacy and safety of bupropion in cancerrelated fatigue, a randomized double blind placebo controlled clinical trial

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Cancer-related fatigue (CRF) is one of the most prevalent complications experienced by cancer patients during and after the process of treatment. Despite conducting a lot of studies, there is no approved therapy to help manage CRF. This study aims to investigate the efficacy of bupropion on CRF. | Efficacy and safety of bupropion in cancerrelated fatigue a randomized double blind placebo controlled clinical trial

TÀI LIỆU LIÊN QUAN

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

A review of manufacture, bioavailability, safety and clinical efficacy of milk thistle phytosome

Efficacy and safety of terbinafine in the treatment of dermatophytosis at Nghean provincipal leprosy, dermatology centre (2015-2016)

Báo cáo y học: "The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial"

Báo cáo y học: "Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy"

Báo cáo y học: " A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults"

Báo cáo khoa học: "The Safety and efficacy of a new self-expandable intratracheal nitinol stent for the tracheal collapse in dogs"

Alterations in Brain and Immune Function Produced by Mindfulness Meditation

Báo cáo y học: " Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 "

Báo cáo y học: " Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study"